BioPharm International magazine has published an article by SGS, exploring the growing significance of mass spectrometry (MS) in support of RNA therapeutics.
The March 2023 issue of BioPharm International magazine features an article by SGS exploring how the development of any therapeutic requires supporting analytics. This is particularly important and challenging for novel, advanced medicines. The emergence of protein-based therapeutics was augmented by contemporaneous advances in mass spectrometry (MS) and the article describes the growing significance of MS in support of RNA therapeutics.
Read our recent article published in BioPharm International to discover more about how the industry is working to resolve the crucial issues of stability and delivery of RNA-based therapeutics.
About SGS
We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for sustainability, quality and integrity. Our 97,000 employees operate a network of 2,650 offices and laboratories, working together to enable a better, safer and more interconnected world.
Amman, Al-Jbeiha, Yajouz Street,
Caracas Building, Entrance No1, 3rd Floor, Office 311, 11193,
Amman, Jordan